• LinkedIn Profile
  • Facebook Profile
  • Twitter Profile
  • Instem Logo
  • Menu
  • Corporate Profile
  • Financial Overview
  • Presentations
  • News
  • Shareholders
  • Annual Reports
  • Investor Contacts

In this section

  • Presentations
  • Research Notes

Research Notes

January 31, 2023

Impressive growth in FY22


December 22, 2022

Major license fee underpins full-year result


September 27, 2022

Another positive period for Instem


September 05, 2022

Largest ever contract validates growth strategy


August 04, 2022

H1 22 – Strong trading and positive outlook


April 26, 2022

FY21: Strong financial performance, strategic transformation


January 26, 2022

Trading in-line, all key metrics improving


September 28, 2021

Strong organic and acquisitive growth


September 01, 2021

A strategic move in Switzerland


July 19, 2021

H1 21 trading: strength across the board


April 12, 2021

FY 20A: Solid growth, despite COVID-19


March 22, 2021

Transformational deal in clinical trial analysis


March 01, 2021

Strengthening the position in Discovery


January 14, 2021

Strong end to 2020 – positioned for growth


September 28, 2020

Momentum remains strong


July 20, 2020

Strong trading, successful fundraise


June 03, 2020

Solid trading, strong delivery


March 25, 2020

Defensive in uncertain times


January 13, 2020

Firing On All Cylinders


November 18, 2019

Acquisition in Safety Assessment


October 16, 2019

Informatics in Focus


September 23, 2019

Building Momentum


July 15, 2019

SEND, SaaS and Strength of Pipeline


April 01, 2019

Another Year of Solid Delivery


January 22, 2019

All Business Areas Performing Well



View All Progressive Equity Research Notes


Share Price

Instem News & Articles on Proactive Investors

Notices

  • Instem Corporate Site
  • Terms & Conditions
  • Privacy Policy
  • Environmental Policy
  • Contact
  • LinkedIn Profile
  • Facebook Profile
  • Twitter Profile

© 2023 Instem Group of Companies